A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

CompletedOBSERVATIONAL

Enrollment

11,316

Participants

Timeline

Start Date

February 26, 2021

Primary Completion Date

February 3, 2022

Study Completion Date

February 3, 2022

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DEVICE

Trelegy Ellipta

Trelegy Ellipta with Furoate/Umeclidinium/Vilanterol

DEVICE

Stiolto Respimat

Stiolto Respimat with Tiotropium Bromide/Olodaterol

DRUG

Furoate/Umeclidinium/Vilanterol

DRUG

Tiotropium Bromide/Olodaterol

Trial Locations (1)

Optum, Eden Prairie